Search

Search results

3115 results found

Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.

Shlyankevich, Julia, Nehal N Mehta, James G Krueger, Bruce Strober, Johann E Gudjonsson, Abrar A Qureshi, Paul W Tebbey, and Alexandra Boer Kimball. 2014. “Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-Related Comorbidities.”. The American Journal of Medicine 127 (12): 1148-53.

Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.

Martin, Mona L, Kelly P McCarrier, Chiun-Fang Chiou, Kenneth Gordon, Alexa B Kimball, Abby S Van Voorhees, Alice B Gottlieb, et al. 2013. “Early Development and Qualitative Evidence of Content Validity for the Psoriasis Symptom Inventory (PSI), a Patient-Reported Outcome Measure of Psoriasis Symptom Severity.”. The Journal of Dermatological Treatment 24 (4): 255-60.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

Strober, Bruce E, Robert Bissonnette, David Fiorentino, Alexa B Kimball, Luigi Naldi, Neil H Shear, Kavitha Goyal, et al. 2016. “Comparative Effectiveness of Biologic Agents for the Treatment of Psoriasis in a Real-World Setting: Results from a Large, Prospective, Observational Study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).”. Journal of the American Academy of Dermatology 74 (5): 851-61.e4.

Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor.

Kimball, A B, E Edson-Heredia, B Zhu, J Guo, T Maeda-Chubachi, W Shen, and M T Bianchi. 2016. “Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor.”. Journal of Drugs in Dermatology : JDD 15 (2): 183-8.

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).

Blauvelt, Andrew, Alexa B Kimball, Matthias Augustin, Yukari Okubo, Michael M Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, and Bruce Strober. 2022. “Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase III Trial (OASIS-1).”. The British Journal of Dermatology 187 (6): 866-77.